Research ExplorerPublicationsTherapie der rezidivierten und fernmetastasierten Plattenepi...

Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs:Highlights des ASCO-Meetings 2015

Standard

Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs:Highlights des ASCO-Meetings 2015. / Bußmann, L; Busch, C-J; Knecht, R.

In: HNO, Vol. 63, No. 9, 09.2015, p. 620-4.

Research output: SCORING: Contribution to journal › Conference article in journal › Research › peer-review

Harvard

Bußmann, L, Busch, C-J & Knecht, R 2015, 'Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs:Highlights des ASCO-Meetings 2015', HNO, vol. 63, no. 9, pp. 620-4. https://doi.org/10.1007/s00106-015-0055-0

APA

Bußmann, L., Busch, C-J., & Knecht, R. (2015). Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs:Highlights des ASCO-Meetings 2015. HNO, 63(9), 620-4. https://doi.org/10.1007/s00106-015-0055-0

Vancouver

Bußmann L, Busch C-J, Knecht R. Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs:Highlights des ASCO-Meetings 2015. HNO. 2015 Sep;63(9):620-4. https://doi.org/10.1007/s00106-015-0055-0

Bibtex

@article{e103e567064442a0a1035657602e7412,
title = "Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs:Highlights des ASCO-Meetings 2015",
abstract = "This year also saw a great number of phase II and III studies presented at the ASCO Annual Meeting, in which new drugs (monoclonal antibodies, small molecules) were investigated as an alternative to or in combination with established mono- and polychemotherapy in patients with recurrences or distance metastases from head and neck squamous cell carcinoma (R/M-HNSCC). The studies now presented here describe the different concepts being applied to drug-based treatment of R/M-HNSCC and illustrate the variety of therapeutic approaches to treatment of recurrences and metastases.",
author = "L Bu{\ss}mann and C-J Busch and R Knecht",
year = "2015",
month = sep,
doi = "10.1007/s00106-015-0055-0",
language = "Deutsch",
volume = "63",
pages = "620--4",
journal = "HNO",
issn = "0017-6192",
publisher = "Springer",
number = "9",

}

RIS

TY - JOUR

T1 - Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs:Highlights des ASCO-Meetings 2015

AU - Bußmann, L

AU - Busch, C-J

AU - Knecht, R

PY - 2015/9

Y1 - 2015/9

N2 - This year also saw a great number of phase II and III studies presented at the ASCO Annual Meeting, in which new drugs (monoclonal antibodies, small molecules) were investigated as an alternative to or in combination with established mono- and polychemotherapy in patients with recurrences or distance metastases from head and neck squamous cell carcinoma (R/M-HNSCC). The studies now presented here describe the different concepts being applied to drug-based treatment of R/M-HNSCC and illustrate the variety of therapeutic approaches to treatment of recurrences and metastases.

AB - This year also saw a great number of phase II and III studies presented at the ASCO Annual Meeting, in which new drugs (monoclonal antibodies, small molecules) were investigated as an alternative to or in combination with established mono- and polychemotherapy in patients with recurrences or distance metastases from head and neck squamous cell carcinoma (R/M-HNSCC). The studies now presented here describe the different concepts being applied to drug-based treatment of R/M-HNSCC and illustrate the variety of therapeutic approaches to treatment of recurrences and metastases.

U2 - 10.1007/s00106-015-0055-0

DO - 10.1007/s00106-015-0055-0

M3 - Konferenzaufsatz in Fachzeitschrift

C2 - 26319430

VL - 63

SP - 620

EP - 624

JO - HNO

JF - HNO

SN - 0017-6192

IS - 9

ER -